Literature DB >> 18199538

Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium.

Nicole Yeager1, Charlene Brewer, Kathy Qi Cai, Xiang-Xi Xu, Antonio Di Cristofano.   

Abstract

Activation of the phosphatidylinositol-3-OH kinase (PI3K) signaling cascade is becoming increasingly recognized as a common feature of thyroid follicular neoplasms. We have recently shown that conditional loss of Pten in the mouse thyroid follicular cells is sufficient to stimulate continuous autonomous growth, leading to a homogeneously hyperplastic gland and to the development of follicular adenomas. Because the PI3K/AKT cascade can activate a plethora of different signaling pathways, it is still unclear which of these may represent the key mitogenic output of PI3K-initiated signaling. Here, we show that the in vivo proliferative response to chronic PI3K activation profoundly relies on the activation of the mammalian target of rapamycin (mTOR)/S6K1 axis, and that mTOR inhibition in Pten mutant mice and cells restores virtually normal proliferation rates, despite the presence of still elevated Akt activity, at least in part by down-regulating cyclins D1 and D3, and without affecting cell survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18199538     DOI: 10.1158/0008-5472.CAN-07-3030

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.

Authors:  Ruixin Liu; Dingxie Liu; Eliana Trink; Ermal Bojdani; Guang Ning; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

2.  Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer.

Authors:  Celine J Guigon; Laura Fozzatti; Changxue Lu; Mark C Willingham; Sheue-Yann Cheng
Journal:  Carcinogenesis       Date:  2010-03-18       Impact factor: 4.944

3.  Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.

Authors:  Roberta Malaguarnera; Kuen-Yuan Chen; Tae-Yong Kim; Jose M Dominguez; Francesca Voza; Bin Ouyang; Sushil K Vundavalli; Jeffrey A Knauf; James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2014-07-16       Impact factor: 5.958

4.  cAMP-dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4.

Authors:  Sara Blancquaert; Lifu Wang; Sabine Paternot; Katia Coulonval; Jacques E Dumont; Thurl E Harris; Pierre P Roger
Journal:  Mol Endocrinol       Date:  2010-05-19

5.  Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals.

Authors:  Terence O'Reilly; Paul Mj McSheehy
Journal:  Transl Oncol       Date:  2010-04       Impact factor: 4.243

6.  Retrospective Study of Sirolimus and Cyclophosphamide in Patients with Advanced Differentiated Thyroid Cancers.

Authors:  Poorni M Manohar; Lauren J Beesley; Jeremy Mg Taylor; Elizabeth Hesseltine; Megan R Haymart; Nazanene H Esfandiari; David A Hanauer; Francis P Worden
Journal:  J Thyroid Disord Ther       Date:  2015-07-17

7.  PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.

Authors:  Kristen Wong; Francesca Di Cristofano; Michela Ranieri; Daniela De Martino; Antonio Di Cristofano
Journal:  Endocr Relat Cancer       Date:  2019-01-01       Impact factor: 5.678

8.  Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females.

Authors:  V G Antico-Arciuch; M Dima; X-H Liao; S Refetoff; A Di Cristofano
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

9.  Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.

Authors:  Kelly A Miller; Nicole Yeager; Kristen Baker; Xiao-Hui Liao; Samuel Refetoff; Antonio Di Cristofano
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

10.  Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer.

Authors:  E M Schaeffer; L Marchionni; Z Huang; B Simons; A Blackman; W Yu; G Parmigiani; D M Berman
Journal:  Oncogene       Date:  2008-09-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.